1,1,1,-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO

Compounds of Formula (IA), IB), IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocort...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ZINDELL RENEE, LIU PINGRONG, BETAGERI RAJASHKHAR, RIETHER DORIS, THOMSON DAVID, HAMMACH ABDELHAKIM, TAKAHASHI HIDENORI, PATEL USHA R, HARCKEN CHRISTIAN H.J.J, WANG JI, RAZAVI HOSSEIN, LEE THOMAS WAI-HO, KUZMICH DANIEL, PROUDFOOT JOHN ROBERT, BEKKALI YOUNES, KIRRANE THOMAS MARTIN, EMMANUEL MICHEL J
Format:	Patent
Sprache:	eng ; srp
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Compounds of Formula (IA), IB), IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds. Jedinjenja sa formulom (IA), (IB), (IC) i (ID) gde R1, R2, R3, R4, R5 i R6 su respektivno definisani ovde za formule (lA), (IB), (IC) i (ID) ili njihov tautomer, pro derivat, solvat ili njihovu sol; farmaceutske kompozicije koje sadrže takva jedinjenja i metode za modulaciju funkcije glukokortikoidnog receptora i metode za lečenje bolesnih stanja ili stanja koja su pod uticajem funkcije glukokortikoidnog receptora ili za koja su karakteristični inf1amatorni, alergijski ili proliferativni procesi kod pacijenata, korišćenjem ovih jedinjenja.